In this issue:
Comparison of cross-sectional imaging modalities for MM diagnosis
Bortezomib before and after high-dose therapy in myeloma
Single-center experience in treating patients with t(4;14) multiple myeloma
Melphalan 140 mg/m2 or 200 mg/m2 for autologous transplantation in myeloma
Real-world outcome and survival of myeloma patients
Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma
Recommendations from the American Society of Clinical Oncology on the use of bone-modifying agents in MM
Assessing the effect of adherence on patient-reported outcomes
Safety and efficacy of selinexor in RRMM
Evidence for heparin sulfate proteoglycan syndecan-1 as a potential therapeutic target for MM treatment
Please login below to download this issue (PDF)